Funding for this research was provided by:
Merck & Co (N/A)
Text and Data Mining valid from 2019-10-07
Received: 21 February 2019
Accepted: 22 August 2019
First Online: 7 October 2019
Ethics approval and consent to participate
: Ethical approval was obtained from an accredited external Institutional Review Board (IRB) for those sites not covered by their own internal IRB. The ethical conduct of this study was performed in accordance with the Declaration of Helsinki and the principles of Good Clinical Practices.
: Not applicable.
: LB declares they have no conflicts to disclose.AK and SKT are employees of Merck & Co.SMG received grants to her institution from: the Commonwealth Department of Health for human papillomavirus (HPV) genoprevalence surveillance post-vaccination; Merck & Co. and GSK to perform phase 3 clinical vaccine trials; Merck & Co. to evaluate HPV in a post-vaccination program; Commonwealth Serum Laboratories for an HPV in cervical cancer study; and the Veterinary Centers of America for a study on the effectiveness of a public health HPV vaccine and a study on the associations of early onset cancers. SMG also received speaking fees from Merck Sharp and Dohme Corp., and Sanofi Pasteur/Merck Sharp and Dohme for work performed in her personal time. Merck & Co. paid for travel and accommodations to present at HPV Advisory board meetings.KY was a paid contractor for Merck & Co. at the time of the study and was an employee of Cubist Pharmaceuticals from December 2014 to July 2015, which was acquired by Merck & Co. in January 2015.ARG is a member of Merck & Co. advisory boards. Her institution has received grants and contracts to support HPV-related research.NL and MR are employees of IMS Health, Barcelona, Spain, which is a paid consultant to Merck & Co.